

REFERENCES

1. UNAIDS. Report on the global AIDS epidemic 2014. [Internet]. Available from: http://www.who.int/hiv/data/epi_core_july2015.png.
2. National AIDS Committee. 2015 THAILAND AIDS RESPONSE PROGRESS REPORT: Reporting Period: Fiscal Year of 2014 [Internet]. 2015. Available from: http://namc.ddc.moph.go.th/namc/document/documentry/1-GARP/2015/20151004%20Final%202015%20GARP_full%20paper%20Eng.pdf.
3. UNAIDS. Report on the global AIDS epidemic 2013. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.
4. UNAIDS. Report on the global AIDS epidemic 2012. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf.
5. WHO, UNAIDS. 2011 Global HIV/AIDS Response Epidemic Update and Health Sector Progress towards Universal Access. Available from: http://www.who.int/hiv/pub/progress_report2011/en/.
6. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. *Clin Infect Dis* 2005;40:458-65.
7. Penta Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, *et al*. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. *HIV Med* 2009;10:591-613.
8. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, *et al*. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. *Clin Infect Dis* 2007;45:918-24.

9. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, *et al.* Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. *Retrovirology* 2009;6:85.
10. AIDSinfo. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: <http://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/45/whats-new-in-the-guidelines>.
11. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: <http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/6/drug-resistance-testing>.
12. WHO. The use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Available from: <http://www.who.int/hiv/pub/guidelines/arv2013/download/en/>.
13. Department of Disease Control, Ministry of Public Health. National Guidelines on HIV/AIDS Diagnosis and Treatment: Thailand 2010. Available from: <http://dpc10.ddc.moph.go.th/km55/aids/ThaiGuidelineonHIVdiagnosisandtreatment2010.pdf>.
14. Department of Disease Control, Ministry of Public Health. Essentials of HIV/AIDS Treatment and Prevention 2014 Thailand. Available from: http://www.thaiaidsociety.org/images/PDF/hiv_pocket_2557_ver2.pdf.
15. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, *et al.* Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med* 2008;359:2233-44.
16. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. *Lancet Infect Dis* 2002;2:93-102.
17. Richman DD, Morton SC, Wrinn T, Hellmann N, Berry S, Shapiro MF, *et al.* The prevalence of antiretroviral drug resistance in the United States. *AIDS* 2004;18:1393-401.

18. Clavel F, Hance AJ. HIV drug resistance. *N Engl J Med* 2004;350:1023-35.
19. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. *Antivir Ther* 2008;13 Suppl 2:15-23.
20. AIDSinfo. Panel on Antiretroviral Therapy and Medical Management of HIVinfected Children. Guidelines for the Use of Antiretroviral Agents in Paediatric HIV Infection. Available from: <http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf>.
21. Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, *et al*. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. *PLoS One* 2009;4:e4096.
22. Flys TS, McConnell MS, Matovu F, Church JD, Bagenda D, Khaki L, *et al*. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. *J Infect Dis* 2008;198:465-9.
23. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, *et al*. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. *N Engl J Med* 1997;336:1337-42.
24. Wasik TJ, Jagodzinski PP, Hyjek EM, Wustner J, Trinchieri G, Lischner HW, *et al*. Diminished HIV-specific CTL activity is associated with lower type 1 and enhanced type 2 responses to HIV-specific peptides during perinatal HIV infection. *J Immunol* 1997;158:6029-36.
25. Ding H, Wilson CM, Modjarrad K, McGwin G, Jr., Tang J, Vermund SH. Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the

- reaching for excellence in adolescent care and health (REACH) project. Arch Pediatr Adolesc Med 2009;163:1100-5.
26. Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, *et al.* Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 2001;183:1732-8.
 27. Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, *et al.* Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther 2006;11:329-34.
 28. Fox JM, Fidler S, Weber J. Resistance to HIV drugs in UK may be lower in some areas. BMJ 2006;332:179-80.
 29. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, *et al.* A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006;42:86-90.
 30. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, Carls H, *et al.* Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006;41:573-81.
 31. Shet A, Berry L, Mohri H, Mehendru S, Chung C, Kim A, *et al.* Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006;41:439-46.
 32. Barreto CC, Nishyia A, Araujo LV, Ferreira JE, Busch MP, Sabino EC. Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 2006;41:338-41.
 33. Sukasem C, Churdboonchart V, Sirisidthi K, Riengrojpitak S, Chasombat S, Watitpun C, *et al.* Genotypic resistance mutations in treatment-naïve and

- treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. *Jpn J Infect Dis* 2007;60:284-9.
34. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, Kamudamas A, *et al.* Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. *HIV Med* 2008;9:322-5.
 35. Apisarnthanarak A, Mundy LM. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. *Clin Infect Dis* 2008;46:1630-1.
 36. Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M, *et al.* Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. *J Infect Dis* 2007;195:1402-10.
 37. Parker MM, Wade N, Lloyd RM, Jr., Birkhead GS, Gallagher BK, Cheku B, *et al.* Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. *J Acquir Immune Defic Syndr* 2003;32:292-7.
 38. Parham L, de Rivera IL, Murillo W, Naver L, Largaespada N, Albert J, *et al.* Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004. *AIDS Res Hum Retroviruses* 2011;27:1055-9.
 39. Castillo J, Arteaga G, Mendoza Y, Martinez AA, Samaniego R, Estripeaut D, *et al.* HIV transmitted drug resistance in adult and pediatric populations in Panama. *Rev Panam Salud Publica* 2011;30:649-56.
 40. Bertagnolio S, Penazzato M, Jordan MR, Persaud D, Mofenson LM, Bennett DE, *et al.* World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries. *Clin Infect Dis* 2012;54 Suppl 4:S254-60.

41. Ngo-Giang-Huong N, Khamduang W, Leurent B, Collins I, Nantasen I, Leechanachai P, *et al.* Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settings. *J Acquir Immune Defic Syndr* 2008;49:465-71.
42. Gelderblom HR, Ozel M, Pauli G. Morphogenesis and morphology of HIV. Structure-function relations. *Arch Virol* 1989;106:1-13.
43. Robinson HL. New hope for an AIDS vaccine. *Nat Rev Immunol* 2002;2:239-50.
44. Fanales-Belasio E, Raimondo M, Suligo B, Butto S. HIV virology and pathogenetic mechanisms of infection: a brief overview. *Ann Ist Super Sanita* 2010;46:5-14.
45. Bushman Lab. HIV Systems Biology [Internet]. 2012. Available from: http://www.hivsystemsbiology.org/wiki/images/e/e0/Lentiviral_genetic_maps.png
46. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. *Science* 1998;280:1880-4.
47. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. *Nat Rev Microbiol* 2012;10:279-90.
48. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. *Cold Spring Harb Perspect Med* 2011;1:a006841.
49. Burke DS. Recombination in HIV: an important viral evolutionary strategy. *Emerg Infect Dis* 1997;3:253-9.
50. Santos AF, Soares MA. HIV Genetic Diversity and Drug Resistance. *Viruses* 2010;2:503-31.
51. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. *AIDS* 2006;20:W13-W23.

52. Essex M. Human Immunodeficiency Viruses in The Developing World. In: Karl Margniorosch FAM, Aaron JS, editors. *Advances in Virus Research*. Volume 53: Academic Press; 1999. p. 71-88.
53. Dey SK, Zahan N, Afrose S, Islam T, Shajahan M, Saha S, *et al*. Molecular epidemiology of HIV in Asia. *HIV & AIDS Review* 2014;13:33-9.
54. Tovanabutra S, Watanaveeradej V, Viputtikul K, De Souza M, Razak MH, Suriyanon V, *et al*. A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. *AIDS Res Hum Retroviruses* 2003;19:561-7.
55. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. *N Engl J Med* 2008;358:1590-602.
56. Centers for Disease Control and Prevention. HIV and it's Transmission. [Internet]. 1999. Available from: <http://www.councilofcommunityservices.com/pdfs/transmission.pdf>
57. Ahmad N. Molecular mechanisms of HIV-1 mother-to-child transmission and infection in neonatal target cells. *Life Sci* 2011;88:980-6.
58. Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. *Rev Med Virol* 2007;17:381-403.
59. Bawdon RE, Gravell M, Hamilton R, Sever J, Miller R, Gibbs CJ. Studies on the placental transfer of cell-free human immunodeficiency virus and p24 antigen in an ex vivo human placental model. *J Soc Gynecol Investig* 1994;1:45-8.
60. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. *Lancet Infect Dis* 2006;6:726-32.
61. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, *et al*. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. *N Engl J Med* 1996;334:1617-23.

62. Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, *et al.* Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. *J Infect Dis* 2009;200:1490-7.
63. Ahmad N. The vertical transmission of human immunodeficiency virus type 1: molecular and biological properties of the virus. *Crit Rev Clin Lab Sci* 2005;42:1-34.
64. Petropoulou H, Stratigos AJ, Katsambas AD. Human immunodeficiency virus infection and pregnancy. *Clin Dermatol* 2006;24:536-42.
65. Report of a Consensus Workshop, Siena, Italy, January 17-18, 1992. Maternal factors involved in mother-to-child transmission of HIV-1. *J Acquir Immune Defic Syndr* 1992;5:1019-29.
66. Domachowske JB. Pediatric human immunodeficiency virus infection. *Clin Microbiol Rev* 1996;9:448-68.
67. Auger I, Thomas P, De Gruttola V, Morse D, Moore D, Williams R, *et al.* Incubation periods for paediatric AIDS patients. *Nature* 1988;336:575-7.
68. Blanche S, Tardieu M, Duliege A, Rouzioux C, Le Deist F, Fukunaga K, *et al.* Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. *Am J Dis Child* 1990;144:1210-5.
69. Scott GB, Hutto C, Makuch RW, Mastrucci MT, O'Connor T, Mitchell CD, *et al.* Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. *N Engl J Med* 1989;321:1791-6.
70. Sundaravaradan V, Saxena SK, Ramakrishnan R, Yedavalli VR, Harris DT, Ahmad N. Differential HIV-1 replication in neonatal and adult blood mononuclear cells is influenced at the level of HIV-1 gene expression. *Proc Natl Acad Sci U S A* 2006;103:11701-6.

71. de Martino M, Tovo PA, Galli L, Gabiano C, Cozzani S, Gotta C, *et al.* Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virus. The Italian Register for Human Immunodeficiency Virus Infection in Children. *J Pediatr* 1991;119:702-9.
72. Krasinski K, Borkowsky W, Holzman RS. Prognosis of human immunodeficiency virus infection in children and adolescents. *Pediatr Infect Dis J* 1989;8:216-20.
73. Chakraborty R. HIV-1 infection in children: a clinical and immunologic overview. *Curr HIV Res* 2005;3:31-41.
74. Tovo PA, de Martino M, Gabiano C, Cappello N, D'Elia R, Loy A, *et al.* Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. *Lancet* 1992;339:1249-53.
75. Rogers MF, Ou CY, Rayfield M, Thomas PA, Schoenbaum EE, Abrams E, *et al.* Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. New York City Collaborative Study of Maternal HIV Transmission and Montefiore Medical Center HIV Perinatal Transmission Study Group. *N Engl J Med* 1989;320:1649-54.
76. Read JS, Committee on Pediatric Aids AAoP. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. *Pediatrics* 2007;120:e1547-62.
77. WHO. Antiretroviral Therapy in Infants and Children: Towards Universal Access. Recommendations for a Public Health approach: 2010 Revision. 2010.
78. Lilian RR, Kalk E, Bhowan K, Berrie L, Carmona S, Technau K, *et al.* Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. *J Clin Microbiol* 2012;50:2373-7.
79. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2010.

80. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, *et al.* Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. *JAMA* 2000;283:1175-82.
81. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, *et al.* Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr* 2002;29:484-94.
82. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. *AIDS* 2008;22:973-81.
83. Cibulka NJ. Mother-to-child transmission of HIV in the United States. Many HIV-infected women are now planning to have children. What are the risks to mother and infant? *Am J Nurs* 2006;106:56-63; quiz 4.
84. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. 2006 [Internet]. Available from: www.who.int/hiv/pub/guidelines/pmtctguidelines3.pdf.
85. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach: 2010 Version. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2010.
86. National AIDS Committee. Thailand National Antiretroviral Treatment Guideline. 2006/2007. [Internet]. 2008. Available from: http://www.who.int/hiv/amds/Thailand_2008.pdf.
87. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, *et al.* Decay characteristics of HIV-1-infected compartments during combination therapy. *Nature* 1997;387:188-91.

88. Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, Carroll A, *et al.* The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. *AIDS* 2003;17:963-9.
89. U S Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection [Internet]. 2015. Available from: <http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm>.
90. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. *Cold Spring Harb Perspect Med* 2012;2:a007161.
91. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2010.
92. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, *et al.* Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;338:853-60.
93. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. *Clin Infect Dis* 2005;41 Suppl 4:S239-46.
94. Stanford University. Stanford HIV drug resistance database: Major HIV-1 Drug Resistance Mutations [Internet]. 2015. Available from: http://hivdb.stanford.edu/pages/download/resistanceMutations_handout.pdf.
95. Paredes R, Clotet B. Clinical management of HIV-1 resistance. *Antiviral Res* 2010;85:245-65.
96. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. *Lancet* 2003;362:2002-11.
97. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, *et al.* Intrapartum exposure to nevirapine and subsequent

- maternal responses to nevirapine-based antiretroviral therapy. *N Engl J Med* 2004;351:229-40.
98. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, *et al.* Response to antiretroviral therapy after a single, peripartum dose of nevirapine. *N Engl J Med* 2007;356:135-47.
99. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, *et al.* Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA* 2010;304:1082-90.
100. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, *et al.* Antiretroviral therapies in women after single-dose nevirapine exposure. *N Engl J Med* 2010;363:1499-509.
101. Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, *et al.* Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. *Clin Infect Dis* 2011;52:514-21.
102. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. *Clin Infect Dis* 2006;42:1608-18.
103. Schutten M. Resistance assays. In: Geretti AM, editor. *Antiretroviral Resistance in Clinical Practice*. London 2006.
104. Karchava M, Pulver W, Smith L, Philpott S, Sullivan TJ, Wethers J, *et al.* Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. *J Acquir Immune Defic Syndr* 2006;42:614-9.
105. Rojas Sanchez P, Holguin A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. *J Antimicrob Chemother* 2014;69:2032-42.

106. WHO. Generic Protocol for Surveillance of Initial Drug-resistant HIV-1 Among Children ,18 Months of Age Newly Diagnosed with HIV. [Internet]. Available from: http://apps.who.int/iris/bitstream/10665/75202/1/WHO_HIV_2012.17_eng.pdf.
107. Shao ER, Kifaro EG, Chilumba IB, Nyombi BM, Moyo S, Gaseitsiwe S, *et al*. HIV-1 drug mutations in children from northern Tanzania. *J Antimicrob Chemother* 2014;69:1928-32.
108. Kityo C, Sigaloff KC, Boender TS, Kaudha E, Kayiwa J, Musiime V, *et al*. HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda. *AIDS Res Hum Retroviruses* 2016.
109. Lolekha R, Sirivichayakul S, Siangphoe U, Pancharoen C, Kaewchana S, Apateerapong W, *et al*. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. *Clin Infect Dis* 2005;40:309-12.
110. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *Southeast Asian J Trop Med Public Health* 2009;40:83-8.
111. Jittamala P, Puthanakit T, Chaiinseard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *Pediatr Infect Dis J* 2009;28:826-30.
112. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, *et al*. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *HIV Med* 2010;11:565-72.

113. ANRS. PCR and Sequencing Procedures: HIV-1 (Version January 2015) [Internet]. 2015. Available from: <http://www.hivfrenchresistance.org/ANRS-procedures.pdf>.
114. Kijak GH, Tovanabutra S, Rerks-Ngarm S, Nitayaphan S, Eamsila C, Kunasol P, *et al*. Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. *J Virol* 2013;87:7265-81.
115. Suriya P ST, editor Molecular Epidemiology and Genetic Characterization of HIV-1 Subtypes in Northern Thailand. IGRC 2015; 2015; Chiang Mai, Thailand (Proceeding).
116. Fokam J, Salpini R, Santoro MM, Cento V, Perno CF, Colizzi V, *et al*. Drug resistance among drug-naïve and first-line antiretroviral treatment-failing children in Cameroon. *Pediatr Infect Dis J* 2011;30:1062-8.
117. Church JD, Mwatha A, Bagenda D, Omer SB, Donnell D, Musoke P, *et al*. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. *AIDS Res Hum Retroviruses* 2009;25:673-7.
118. Kuhn L, Hunt G, Technau KG, Coovadia A, Ledwaba J, Pickerill S, *et al*. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. *AIDS* 2014;28:1673-8.
119. Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, *et al*. HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. *Pediatr Infect Dis J* 2008;27:457-9.
120. de Mulder M, York VA, Wiznia AA, Michaud HA, Nixon DF, Holguin A, *et al*. HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA. *HIV Med* 2014;15:135-43.

121. Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, *et al.* Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. *Antivir Ther* 2005;10:791-802.
122. Neogi U, Sahoo PN, De Costa A, Shet A. High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infection. *BMC Infect Dis* 2012;12:317.
123. Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M, *et al.* Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. *AIDS Res Hum Retroviruses* 2010;26:563-8.
124. Nair MKC. Principles of perinatal and pediatric HIV/AIDS 2012 May 1, 2012. 796-7 p.
125. Dumans AT, Barreto CC, Santos AF, Arruda M, Sousa TM, Machado ES, *et al.* Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. *Infect Genet Evol* 2009;9:62-70.
126. Jullaksorn D, Boonchawalit S, Uttiyoung J, Soonthornsata B, Yowang A, Krathong N, *et al.* Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naïve Thai patients. *Southeast Asian J Trop Med Public Health* 2010;41:347-57.
127. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, *et al.* Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. *Int J Epidemiol* 2007;36:1009-21.

128. Mofenson LM. Perinatal exposure to zidovudine--benefits and risks. *N Engl J Med* 2000;343:803-5.
129. Lidstrom J, Li Q, Hoover DR, Kafulafula G, Mofenson LM, Fowler MG, *et al.* Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. *AIDS* 2010;24:381-6.
130. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, *et al.* Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. *J Infect Dis* 2005;192:24-9.
131. Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, *et al.* Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. *J Acquir Immune Defic Syndr* 2005;40:24-9.
132. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, *et al.* Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. *AIDS* 2005;19:2167-9.
133. Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. *Lancet* 2007;370:1668-70.
134. Martinson NA, Ekouevi DK, Dabis F, Morris L, Lupodwana P, Tonwe-Gold B, *et al.* Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. *J Acquir Immune Defic Syndr* 2007;45:206-9.
135. Lockman S. Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. *Curr Opin HIV AIDS* 2008;3:166-72.
136. Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, *et al.* Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. *Clin Infect Dis* 2010;50:1405-14.

137. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, *et al.* Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. *J Infect Dis* 2001;183:1688-93.
138. Kiertiburanakul S, Pinsai S, Chantratita W, Pasomsub E, Leechawengwongs M, Thipmontree W, *et al.* Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay. *PLoS One* 2016;11:e0147945.
139. Weidle PJ, Nesheim S. HIV drug resistance and mother-to-child transmission of HIV. *Clin Perinatol* 2010;37:825-42, x.
140. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, *et al.* Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). *AIDS* 2001;15:1951-7.
141. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, *et al.* Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. *J Infect Dis* 2005;192:16-23.
142. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. *AIDS* 2006;20:995-1002.
143. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, *et al.* Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. *Proc Natl Acad Sci U S A* 2006;103:7094-9.
144. Flys TS, Mwatha A, Guay LA, Nakabiito C, Donnell D, Musoke P, *et al.* Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. *AIDS* 2007;21:2077-82.

145. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, *et al.* Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. *AIDS Res Hum Retroviruses* 2002;18:243-8.
146. Pursuing Later Treatment Options IptftCoOHIVERE, Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, *et al.* Risk of triple-class virological failure in children with HIV: a retrospective cohort study. *Lancet* 2011;377:1580-7.
147. Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, *et al.* Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. *Med Care* 2005;43:III15-22.
148. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, *et al.* High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. *AIDS* 2007;21:2503-11.
149. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, Ussery M, *et al.* Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. *J Clin Microbiol* 2007;45:517-21.
150. Bertagnolio S, Soto-Ramirez L, Pilon R, Rodriguez R, Viveros M, Fuentes L, *et al.* HIV-1 drug resistance surveillance using dried whole blood spots. *Antivir Ther* 2007;12:107-13.
151. Monleau M, Aghokeng AF, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, *et al.* Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. *J Clin Microbiol* 2014;52:578-86.
152. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current


knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS
Rev 2010;12:195-208.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF PUBLICATIONS

1. **Girdthep, N.**, Samleerat, T. HIV Drug Resistance in Newly HIV-Infected Infants in Thailand. International Graduate Research Conference 2015. Chiang Mai, Thailand. December 11, 2015. (Proceeding).
2. Samleerat, T., **Girdthep, N.**, Ngo-Giang-Huong, N., Sirirungsri, W. HIV Drug Resistance Mutations Among Newly Diagnosed HIV-infected Infants in Thailand. The 8th International Workshop on HIV Pediatrics. Durban, South Africa. July 15-16, 2016. (Poster presentation).



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved